On August 20, 2024 PDX Pharma reported the company was granted a new U.S. Patent (US12059500) on August 13, 2024, marking the third U.S. patent for our ARAC technology! ARAC is based on our innovative Pdx-NP nanoparticle platform, which co-delivers antigen release agents and immune checkpoint inhibitors to elicit a potent anti-tumor immune response (Press release, PDX Pharmaceuticals, AUG 20, 2024, View Source [SID1234646304]). The key claims in this patent include PD-L1 antibody-conjugated Pdx-NP loaded with "any" cancer therapeutics. This new addition to our patent portfolio not only extends our protection but also strengthens our commitment to advancing the ARAC pipeline. We are incredibly proud of this achievement, made possible by our dedicated team members and inventors, Drs. Moataz Reda and Worapol (Boom) Ngamcherdtrakul, along with our OHSU collaborator and PDX Pharma’s CEO, Dr. Wassana Yantasee. Stay tuned for more exciting updates!

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!